Novo Nordisk has leading positions in diabetes and obesity ... and the company remains supply-constrained to match demand ...

Moving ahead, Rob Rowe, Regional Research Director and Head of Global Strategy at a large US bank is ‘ tactically bullish ’ on the back of continuing tech recovery and the markets “pricing in a soft ...

This week, Roche RHHBY announced its third-quarter and nine-month results. Sanofi SNY confirmed that it is holding exclusive ...

Xeris is recognized for solid growth and innovative platforms. Learn more about XERS stock and why it's considered a Strong ...

The U.S. Food and Drug Administration has approved Iterum Therapeutics' oral antibiotic to treat a type of urinary tract ...

Semaglutide medications — such as Ozempic, the popular diabetes medication — have been linked to a reduced risk of Alzheimer’s disease for certain groups, a new study finds.

Sanofi and CD&R entered into exclusive negotiations for the potential sale and purchase of a 50% controlling stake in Opella.

Wegovy and similar weight-loss medications are becoming widely prescribed for teenagers with obesity, but little is known ...

The U.K. government issued a new warning aimed at the misuse of GLP-1 therapies by those who don’t qualify for the meds but are instead using them for quick-fix weight loss.

As the demand for weight loss injectables soars, so too does the market for off-brand alternatives, some of which may not be ...

Karan Johar's noticeable weight loss has sparked rumours about his possible use of Ozempic, a diabetes drug known for its ...

A new study found a link between NovoNordisk’s blockbuster drug Ozempic and a reduced risk of Alzheimer’s disease. 23andMe, ...